Therapeutic MAbs market - Is biologics the answer to rising disease incidence?

10 April 2012

Existing adoption rates and commercial success of launched monoclonal antibodies (MAbs) for therapeutics have established a strong platform for these products. Broadening the horizontal indications for existing MAbs, expanding their applications in new therapeutic areas and developing innovative and faster drug delivery mechanism are the current trends in the MAbs market, according to market research firm Frost & Sullivan.

MAbs are mono-specific high molecular weight complex proteins which are capable of post translational modifications like glycosylation. They are predominantly used in the treatment of cancer and autoimmune and inflammatory disorders. Other areas include cardiovascular and infectious diseases and organ transplants. Over 45 MAbs are currently used. Drugs developed for cancer and rheumatoid arthritis (RA) account for 75 % of the total market.

European MAb market set to reach $42.37 billion in 2018

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >